Galantamine

Galantamine is a type of acetylcholinesterase inhibitor. It is an alkaloid extracted from the bulbs and flowers of Galanthus nivalis (common snowdrop), Galanthus caucasicus (Caucasian snowdrop), Galanthus woronowii (Voronov's snowdrop), and other members of the family Amaryllidaceae, such as Narcissus (daffodil), Leucojum aestivum (snowflake), and Lycoris including Lycoris radiata (red spider lily). It can also be produced synthetically. Galantamine is used clinically for treating early-stage Alzheimer's disease and memory impairments, although it has had limited success with the more advanced condition of dementia. While the exact mechanism of galantamine in treating Alzheimer's disease is unknown, it is hypothesized to exert its therapeutic effects by enhancing cholinergic function. Galantamine inhibits the activity of acetylcholinesterase, an enzyme that catalyzes the breakdown of the neurotransmitter acetylcholine. This action elevates and prolongs synaptic acetylcholine concentrations, increasing the availability of acetylcholine to its receptors. The cholinergic system is involved in a variety of functions relevant to Alzheimer's symptomology, such as memory processing, reasoning, and thinking. Galantamine may cause serious adverse effects, such as stomach bleeding, liver injury or chest pain. Galantamine was isolated for the first time from bulbs of Galanthus nivalis (common snowdrop) in the Soviet Union in the 1940s. The active ingredient was extracted, identified, and studied, in particular in relation to acetylcholinesterase (AChE)-inhibiting properties. The first industrial process was developed in 1959. However, it was not until the 1990s when full-scale synthesis was upscaled and optimized.